Dr. Sonneveld - First Analysis of HOVON-65/GMMG-HD4 Randomized Phase III Trial Comparing Bortezomib, Adriamycine, Dexamethasone (PAD) Vs VAD as Induction Treatment Prior to High Dose Melphalan (HDM) in Patients with Newly Diagnosed Multiple Myeloma (MM)
Pieter Sonneveld, MD, PhD Erasmus Medical Center Rotterdam, Netherlands Member, IMF Board of Scientific Advisors
To view the video full screen, click on the small
button next to the volume control in the
lower right hand corner.